MedTrace Logo

Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy

NCT00745498 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2015-12-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.

Conditions

  • Proliferative Diabetic Retinopathy
  • Vitreous Hemorrhage

Interventions

DRUG

Bevacizumab

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Kyu Hyung Park, M.D. · Seoul National Univeristy Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-10-31
Completion
2010-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745498 on ClinicalTrials.gov